Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | OGA | O60502 | 3/20 | 0.46 |
| ▸ | ACACB | O00763 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20443215 | 0.87 | OGA (0.58) | KDM4ENPC1RAB9AMEN1KMT2A | |
| SCHEMBL9946220 | 0.81 | KDM4E (0.64) | KDM4ENPC1RAB9AMEN1KMT2A | |
| SCHEMBL19983435 | 0.80 | KDM4E (0.63) | KDM4ENPC1RAB9AMEN1KMT2A | |
| SCHEMBL2455500 | 0.78 | KDM4E (0.60) | KDM4ENPC1RAB9AMEN1KMT2A | |
| SCHEMBL890101 | 0.78 | OGA (0.55) | KDM4EOGAALDH1A1ACHEDHFR | |
| SCHEMBL19450847 | 0.77 | KDM4E (0.52) | KDM4ENPC1RAB9AMEN1KMT2A | |
| SCHEMBL19434393 | 0.77 | KDM4E (0.52) | KDM4ENPC1RAB9AMEN1KMT2A | |
| SCHEMBL19434339 | 0.77 | KDM4E (0.52) | KDM4ENPC1RAB9AMEN1KMT2A | |
| SCHEMBL17471338 | 0.77 | KDM4E (0.59) | KDM4ENPC1RAB9AMEN1KMT2A | |
| SCHEMBL1126338 | 0.76 | OGA (0.53) | KDM4EOGAALDH1A1ACHEPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218214-A1 | Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof | VANDERBILT UNIVERSITY | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218214-A1 | Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof | BMP1, BMP4, BMP2 | KDM4E 802/4885NPC1 2775/4885RAB9A 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.